Evidation has released longitudinal survey findings from more than 165,000 people showing that adoption of GLP-1 weight-management medicines is expanding but remains highly uneven across age, sex and income groups. Among 119,000 respondents actively trying to lose weight, 24% had ever used prescription weight-management medication and 15% had ever used a GLP-1 medicine, positioning the data as a real-world commercial and evidence signal rather than an efficacy or safety study.
The findings suggest that the GLP-1 market remains far from fully penetrated, even after several years of intense patient demand, expanded manufacturing and wider clinical acceptance of pharmacological obesity treatment. However, the gap between people attempting to lose weight and those who have used prescription medicines cannot be treated as a straightforward forecast of future sales.
Instead, Evidation’s data reveal a highly segmented treatment environment in which income, insurance design, healthcare engagement, prescribing patterns and willingness to remain on therapy may be as important as clinical eligibility. The next phase of GLP-1 growth is therefore likely to depend less on awareness and more on whether healthcare systems can convert interest into appropriate, affordable and sustained treatment.
Why Evidation’s 15% GLP-1 use rate signals headroom without proving a market forecast
The most commercially significant figure is not simply the proportion of respondents who had tried a GLP-1 medicine. It is the much larger population that was actively attempting to lose weight but had never entered a prescription weight-management pathway.
Among respondents trying to lose weight without previous prescription treatment, 76% had a body mass index of at least 25 and 39% had a body mass index of at least 30. These thresholds indicate a large population that may warrant clinical assessment for overweight, obesity or related metabolic conditions. They do not establish that every respondent is medically eligible for a GLP-1 medicine.
Eligibility can depend on comorbidities, contraindications, treatment history, pregnancy status, medication interactions, individual risk profiles and whether a clinician determines that pharmacological treatment is appropriate. Some respondents may also prefer lifestyle programmes, nutritional support, behavioural treatment or bariatric procedures. Others may be unwilling to accept long-term medication, gastrointestinal adverse effects or the possibility of weight regain following discontinuation.
The 15% lifetime-use figure should therefore be viewed as an indicator of market headroom rather than a measure of immediately addressable demand. It demonstrates that adoption remains incomplete, but it does not reveal how many untreated respondents have sought a prescription, been denied coverage, rejected therapy or never discussed medical weight management with a clinician.
For pharmaceutical manufacturers, payers and healthcare providers, the practical opportunity lies in understanding this conversion funnel. Awareness, clinical assessment, prescription, access, treatment initiation and long-term persistence are separate stages. A large population at the top of that funnel does not guarantee durable demand at the bottom.
How income, gender and age differences expose a fragmented treatment access system
Household income produced one of the clearest differences in the Evidation findings. GLP-1 experience reached 17% among respondents with household income of at least $150,000, compared with 9% among those with income below $25,000.
That gap is unlikely to reflect biological differences in who can benefit from obesity treatment. It more plausibly reflects differences in insurance coverage, out-of-pocket affordability, access to specialists, employer health benefits, continuity of care and the ability to navigate prior-authorisation requirements.
Higher-income patients may also be better positioned to absorb expenses when coverage is interrupted or denied. Lower-income patients can face a more fragile treatment pathway in which a coverage change, shortage, copayment increase or missed clinical appointment leads to discontinuation.
The gender divide was similarly notable. GLP-1 experience reached 15% among women and 9% among men, despite broadly similar average body mass index levels among respondents without previous prescription weight-management treatment.
This may reflect greater engagement by women with weight-management services, different patterns of healthcare utilisation, stronger social pressure surrounding body weight or differences in prescribing conversations. It could also indicate that obesity-related risks in men are being addressed later, through diabetes, cardiovascular or sleep medicine pathways rather than dedicated weight-management services.
Adults aged 40 to 49 and 50 to 59 recorded the highest GLP-1 experience, at 17% and 19%, respectively. Middle-aged adults are more likely to have accumulated weight-related conditions that strengthen the medical rationale for treatment, while also remaining commercially insured through employment.
Younger adults may face weaker insurance coverage or less frequent engagement with healthcare services. Older adults may encounter different reimbursement rules, concerns about loss of lean mass, polypharmacy or treatment priorities shaped by multiple chronic conditions.
These patterns show why broad consumer marketing alone cannot resolve uneven adoption. Manufacturers may identify underpenetrated demographic groups, but any expansion strategy must remain grounded in appropriate clinical assessment rather than treating every low-use population as an untapped promotional segment.
Why rapid category growth may conceal a much harder persistence and retention problem
Reported GLP-1 experience rose from 9% in May 2025 to 12% in May 2026, accounting for nearly all of the growth in prescription weight-management medication use during that period. This indicates that the prescription obesity market is increasingly becoming a GLP-1 market rather than a broadly diversified anti-obesity medication market.
The commercial risk is that initiation can create the appearance of rapid category expansion while concealing weak long-term persistence. Large real-world studies have found substantial discontinuation during the first year, particularly among patients without type 2 diabetes. More recent evidence has also suggested that fewer than one in four adults with overweight or obesity but without diabetes remained on any GLP-1 receptor agonist 12 months after initiation.
Patients may stop because of adverse effects, treatment cost, coverage changes, shortages, insufficient weight loss, unrealistic expectations or dissatisfaction after weight loss plateaus. Some may switch between semaglutide, tirzepatide or other agents rather than leave the category entirely. Others may discontinue and later restart after weight regain.
This distinction matters for both clinical interpretation and market modelling. A patient who has ever used a GLP-1 medicine may have taken it continuously for several years, stopped after several weeks or switched repeatedly between products. Lifetime exposure therefore provides evidence of reach, but not evidence of adherence, persistence or durable clinical benefit.
For manufacturers, long-term value may increasingly depend on patient-support infrastructure rather than acquisition alone. Dose-escalation support, adverse-effect management, nutritional care, resistance-training guidance, coverage assistance and switching protocols may determine whether patients remain within the treatment pathway.
Payers will also require stronger evidence that sustained treatment reduces downstream clinical events and generates value that justifies long-duration expenditure. A market with millions of initiations but high churn could be far less attractive than headline adoption rates imply.
What broader indications and oral options could change the next phase of GLP-1 adoption
The GLP-1 category is no longer defined only by weight reduction. Wegovy, the semaglutide product developed by Novo Nordisk, has indications extending into cardiovascular risk reduction and metabolic dysfunction-associated steatohepatitis. Zepbound, the tirzepatide product developed by Eli Lilly and Company, is also approved for moderate to severe obstructive sleep apnea in adults with obesity.
These indications can move prescribing beyond dedicated obesity clinics and into cardiology, hepatology, sleep medicine and broader metabolic care. The commercial effect could be substantial because treatment discussions may increasingly begin with a serious obesity-related complication rather than a weight-loss request.
Oral treatment options could further broaden the addressable population. Oral Wegovy and Foundayo, the orforglipron tablet developed by Eli Lilly and Company, remove the need for self-injection and may appeal to patients who have resisted injectable therapy.
However, oral administration does not automatically solve the major barriers identified by Evidation. A daily tablet can still be expensive, poorly covered or discontinued because of adverse effects. Daily dosing may also create adherence challenges that differ from once-weekly injections.
New formulations may lower one form of friction while leaving the economic and behavioural barriers largely unchanged. The expansion of treatment choices could also make the market more complex, with clinicians balancing efficacy, tolerability, dosing convenience, comorbidities, insurance restrictions and patient preferences.
The strongest commercial advantage may therefore belong to products and support systems that demonstrate not only substantial weight loss but also sustained use, manageable adverse effects and clinically relevant benefits across obesity-related diseases.
What Evidation’s longitudinal real-world model offers pharma teams that claims data cannot
Evidation’s research model combines repeated participant engagement with patient-reported outcomes, digital measurements and permissioned clinical information. This approach can capture aspects of the treatment journey that conventional prescription claims may miss.
Claims can identify that a medicine was dispensed, but they may not reveal why the patient requested treatment, why the clinician selected a particular product, whether the patient delayed taking it or what caused treatment to stop. Direct participant research can explore awareness, expectations, preferences, affordability concerns, adverse effects and the everyday burden of remaining on therapy.
That information could support clinical development, market-access planning, post-market research and the design of adherence programmes. It could also help manufacturers recruit participants for pragmatic studies or examine how treatment experiences differ between demographic groups.
The limitations are equally important. The findings are observational and largely dependent on participant-reported information. They do not establish that income, age or gender directly caused the differences in medication use.
The public summary does not provide a full account of recruitment methods, response rates, survey attrition, demographic weighting or how closely the cohort represents the broader United States population. Digitally engaged participants who consent to longitudinal health research may differ from people with limited internet access, lower health literacy or weaker engagement with healthcare services.
The study also uses GLP-1 experience, which includes current and previous use. This is useful for measuring category exposure but insufficient for distinguishing sustained treatment from brief or interrupted use.
Evidation’s dataset may therefore be most valuable as a hypothesis-generating and market-segmentation resource. Its strongest contribution is not proving how the entire population behaves, but revealing which questions require more rigorous investigation.
Why the untreated population should not be confused with an immediately addressable market
The phrase “actively trying to lose weight” covers a wide range of intentions, clinical needs and treatment preferences. It can include individuals pursuing modest lifestyle changes, people with medically significant obesity, patients attempting to prevent diabetes and consumers motivated primarily by appearance.
This broad definition is useful for understanding public interest, but it creates challenges for commercial interpretation. The difference between 119,000 respondents trying to lose weight and the smaller group using GLP-1 medicines does not represent a single block of unmet pharmaceutical demand.
Some people may achieve their goals without medication. Some may not meet prescribing criteria. Others may be suitable candidates but remain unwilling to begin a potentially long-term treatment.
Affordability can also suppress demand in ways that consumer surveys cannot fully capture. A respondent may express interest but withdraw after learning the cost, discovering an insurance exclusion or confronting repeated authorisation requirements. Another may obtain medication through a temporary programme but lose access later.
The addressable market must therefore be calculated through several filters, including clinical eligibility, willingness to use medication, prescriber capacity, insurance coverage, product availability and expected persistence.
Evidation’s findings support the conclusion that substantial growth remains possible. They do not support the more aggressive assumption that every untreated respondent will eventually become a long-term GLP-1 user.
What clinicians, regulators and manufacturers will need to measure next
The most important next step is to separate lifetime exposure from current use and sustained use. Future analyses should identify how many participants are actively taking a GLP-1 medicine, how long they remain on treatment and what proportion switch, pause or restart.
Reasons for non-initiation and discontinuation will be equally important. Cost, coverage denial, adverse effects, supply interruptions, insufficient response, fear of injections and personal preferences should be measured separately rather than combined into a general access category.
Researchers will also need to examine how experiences differ by insurance type, geography, race, ethnicity, clinical indication and prescribing setting. The demographic highlights released by Evidation are valuable, but they represent only part of the access landscape.
Clinical outcomes should be connected to treatment duration whenever possible. Weight change, glycaemic control, cardiovascular events, sleep apnea outcomes, liver disease progression, physical function and patient-reported quality of life will help determine whether expanded use produces sustained health benefits.
Regulators and healthcare systems will also be watching how approved medicines interact with compounded and other unapproved supply channels. Patients moving between products may face differences in dosing, quality oversight, clinical support and continuity of care.
For manufacturers, a clearer picture of the patient journey could reshape commercial priorities. The next competitive battleground may not be simply which product produces the greatest average weight reduction. It may be which treatment pathway keeps appropriate patients engaged, supported and clinically benefiting for the longest period.
Why durable access rather than awareness will decide the GLP-1 market’s commercial ceiling
The strongest interpretation of Evidation’s findings is that the GLP-1 market remains early in its development, but future expansion will not be evenly distributed or operationally simple. Large numbers of people remain outside prescription weight-management pathways, yet many of the barriers separating them from treatment are structural rather than promotional.
The income gradient points towards affordability and insurance design. The gender and age gaps point towards different healthcare behaviours and prescribing pathways. The persistence evidence across the wider market shows that starting therapy is not the same as remaining successfully treated.
This creates a dual opportunity for the pharmaceutical sector. Manufacturers can reach populations that have historically lacked access to effective obesity medicines, while generating evidence and support systems that improve sustained treatment. The corresponding risk is that the category expands primarily among people with the strongest insurance and financial resources, reinforcing existing health inequalities.
Evidation’s cohort provides a valuable view of how patients are interacting with a rapidly changing therapeutic market. Its findings do not establish the final size of that market, but they reveal the variables that are likely to determine it.
The GLP-1 industry has already demonstrated that it can generate extraordinary patient interest. The harder test is whether it can build treatment pathways that are affordable, clinically appropriate and durable across a much broader population.
Evidation GLP-1 study reveals major growth runway but exposes widening access gaps added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →